A.P.L.
LOE ApproachingBLAINJECTIONINJECTABLE
Approved
Dec 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
A.P.L. is a biologic injectable approved in 1974 by Ferring Pharmaceuticals under a Biologics License Application. The specific indication, mechanism of action, and therapeutic class are not publicly documented in available data. This product represents a mature, legacy biologic asset with a long clinical history.
LOE Approaching
As a legacy biologic nearing loss of exclusivity with low job openings (0 linked positions), commercial teams are likely minimal or consolidating in preparation for generic/biosimilar erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on A.P.L. offers limited career growth given zero linked job openings and imminent LOE status. This role is suitable for professionals managing legacy assets or seeking transition experience into biosimilar defense or product discontinuation.
Brand ManagerField Sales
Worked on A.P.L. at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.